Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lübbert

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Journal of Biological Response Modifiers|October 1, 1990
Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administrationF Herrmann, A Ganser, A Lindemann, et al.
Leukemia|July 1, 1991
Stable methylation patterns of MYC and other genes regulated during terminal myeloid differentiationM Lübbert, W Salser, M Prokocimer, et al.
Blood|October 15, 1991
Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expressionF Herrmann, M Andreeff, H J Gruss, et al.
Bone Marrow Transplantation|March 1, 1997
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantationS Fetscher, M Lübbert, L Kanz, et al.
Leukemia|November 1, 1990
Gamma-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factorD Riedel, A Lindemann, J Otto, et al.
Leukemia|August 31, 2016
Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDSH Bertz, M Lübbert, K Ohneberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsP Wijermans, M Lübbert, G Verhoef, et al.
Bone Marrow Transplantation|April 14, 2009
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patientsM Lübbert, H Bertz, B Rüter, et al.
Bone Marrow Transplantation|September 1, 2009
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allograftingM Lübbert, H Bertz, R Wäsch, et al.
Oncogene|February 11, 1992
Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemiaM Lübbert, J Mirro, G Kitchingman, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Journal of Biological Response Modifiers|October 1, 1990
Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administrationF Herrmann, A Ganser, A Lindemann, et al.
Leukemia|July 1, 1991
Stable methylation patterns of MYC and other genes regulated during terminal myeloid differentiationM Lübbert, W Salser, M Prokocimer, et al.
Blood|October 15, 1991
Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expressionF Herrmann, M Andreeff, H J Gruss, et al.
Bone Marrow Transplantation|March 1, 1997
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantationS Fetscher, M Lübbert, L Kanz, et al.
Leukemia|November 1, 1990
Gamma-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factorD Riedel, A Lindemann, J Otto, et al.
Leukemia|August 31, 2016
Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDSH Bertz, M Lübbert, K Ohneberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsP Wijermans, M Lübbert, G Verhoef, et al.
Bone Marrow Transplantation|April 14, 2009
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patientsM Lübbert, H Bertz, B Rüter, et al.
Bone Marrow Transplantation|September 1, 2009
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allograftingM Lübbert, H Bertz, R Wäsch, et al.
Oncogene|February 11, 1992
Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemiaM Lübbert, J Mirro, G Kitchingman, et al.
Pageof 12